Garo H. Armen

Garo H. Armen, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Agenus Inc, Protagenic Therapeutics, Inc.\new and MiNK Therapeutics, Inc. Over a trading history stretching from 2 July 2020 to 21 August 2026, the count stands at 108 filings.

Both buying and selling appear: 9 purchases worth €414k, against 1 sale worth €86k. Purchases outweigh sales by €328k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 95 share grants and 1 option exercise. Since January 2026: 7 purchases and no sales on the market.

The median purchase comes to €4,193. Measured against the company's value, the median purchase equals 0.082% of market capitalisation, across 7 purchases where it is known. Across 9 purchases, this insider has always bought alone, with no colleague buying within 30 days.

Most recently, on 24 August 2026, the filings show an open-market purchase worth €11k in Protagenic Therapeutics, Inc.\new. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.